Every so often, one of Europe’s biotechs finds itself on the brink of becoming a fully integrated biopharmaceutical company, an event that this time around features Galapagos NV.
Galapagos and its US partner, Gilead Sciences Inc., announced on 15 August that the marketing submission for their oral...







